Find and Pitch Jounalists, Get Your Story Covered

Tags: apps instagram Meta service outage multiple sclerosis

	Profile	Recent Articles on Subject
1	1387865 PharmaTimes PharmaTimes Media Ltd. Digital health news. Surrey, United Kingdom pharmahealthdigital healthmhealthNHSmarketingcommunicationsclinicaljobsMSL	NICE nod for Darzalex with lenalidomide and dexamethasone - over 1 year ago
2	Frank Vinluan MedCity News Medical innovation tracker. MedCity, USA medicalinnovation	ASH 2024 Recap: Movement in Multiple Myeloma, Cell Therapy, Sickle Cell Disease & More - 13 days ago GSK Multiple Myeloma Drug’s DREAMM Comeback Continues With Phase 3 Data at ASH - 16 days ago FDA Rejection Delays Regeneron From Competing With J&J, Pfizer in Multiple Myeloma - 4 months ago Cell Therapy Now Set to Reach More Patients With Expanded FDA Nod for 2 Multiple Myeloma Drugs - 9 months ago
3	John Pinching PharmaTimes Next-gen biopharma company. La Jolla, California biopharmadrugsdevices	Cellenkos presents promising phase 1b data for CK0804 in myelofibrosis - 16 days ago Arcellx to present positive data on multiple myeloma treatments - about 2 months ago Darzalex subcutaneous regimen approved by European Commission - 2 months ago Scotland first in UK to approve new myeloma treatment - 4 months ago
4	Alana Hippensteele, Managing Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	Daratumumab Demonstrates Significant Benefit in High-Risk Smoldering Myeloma: Results from the Phase 3 AQUILA Study - 17 days ago Advances in CAR T-Cell Therapy and Bispecifics for Relapsed/Refractory Multiple Myeloma - 2 months ago Relapsed/Refractory Multiple Myeloma Treatment Advances With Three BiTE Therapy Options - 9 months ago Subcutaneous Daratumumab Plus VRd Significantly Improved PFS, Increased Depth of Response in Patients With Newly Diagnosed Multiple Myeloma - about 1 year ago AI Model Can Differentiate Prefibrotic Primary Myelofibrosis From Essential Thrombocythemia With High Accuracy - about 1 year ago
5	MedPage Today Staff MedPage Today Explains healthcare complexities. Not endorsements. New York, New York Healthcare journalism	'You Don't Just Shoot an Arrow at It': What We Heard This Week - 17 days ago
6	Amir Ali, PharmD, BCOP Pharmacy Times Clinical Hem/Onc Pharmacist. USC Assistant Professor. Founder of OncologySolutionsRx. Los Angeles, CA Healthcareoncologypharmacyeducation	Final Thoughts - about 1 month ago Personalizing Treatments and Patient Education - about 2 months ago Evaluating New Data for Transplant-Eligible Patients With NDMM: PERSEUS, IsKia, and GMMG HD7 - 2 months ago Real-World Considerations for New Therapies - 2 months ago Impact of Transplant Eligibility on Treatment Selection - 3 months ago
7	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	STAT+: Early data from Arcellx, Gilead suggest CAR-T for multiple myeloma could offer safety benefit - about 2 months ago
8	Mike Bassett MedPage Today Explains healthcare complexities. Not endorsements. New York, New York Healthcare journalism	Real World CAR T-Cell Therapy Outcomes 'Favorable' in Relapsed/Refractory Myeloma - 3 months ago All-Oral Therapy Promising in Higher-Risk MDS, CMML - 11 months ago
9	Greg Laub MedPage Today Director of Video at MedPage Today. Screenwriter, previous managing editor. videographyscreenwritingediting	Belantamab Mafodotin: The Comeback Drug in Multiple Myeloma - 6 months ago Daratumumab Added to Standard Therapy Improves PFS in Multiple Myeloma - 12 months ago Why Some Myeloma Patients Refuse Stem Cell Transplant - about 1 year ago
10	Ian Ingram MedPage Today Deputy Managing Editor. MedPage Today. New York, New York medical journalismediting	FDA Approves Earlier Use of CAR-T Products for Myeloma - 9 months ago Benefits of Myeloma Regimens in the Real World Fall Well Short of Trials - about 1 year ago

Journalists covering Multiple Myeloma